In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Merck, Pfizer team up on Phase III trials and future commercialization of Pfizer's SGLT2 inhibitor for Type II diabetes

Executive Summary

Merck & Co. Inc. and Pfizer Inc. have entered into a worldwide (excluding Japan) collaboration surrounding the development and commercialization of Pfizer’s oral sodium-dependent glucose cotransporter (SGLT2) inhibitor ertugliflozin (PF04971729), which will enter Phase III trials for Type II diabetes later this year.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing
    • Co-Promotion

Related Companies

Advertisement
UsernamePublicRestriction

Register